Dostarlimab-gxly Approved for Recurrent/Advanced Endometrial Cancer

The FDA has granted accelerated approval to dostarlimab-gxly (JemperliĀ®, GlaxoSmithKline) for patients with mismatch repair deficient recurrent or advanced endometrial cancer that has progressed on or after a prior platinum-containing chemotherapy. "The prognosis for patients with a diagnosis of advanced or recurrent endometrial cancer is poor, and, to our knowledge, there are no accepted consensus-based guidelines for standard of care after the disease progresses while undergoing or after treat...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright Ā© 2021 Oncology Data Advisor. All rights reserved.